Articles by Lauren Dembeck, PhD
Real-world weight loss with semaglutide or tirzepatide is lower due to early discontinuation and low maintenance dosing.
Sacituzumab + pembrolizumab improves PFS vs chemo in PD-L1+ TNBC, per ASCENT-04/KEYNOTE-D19 phase 3 trial at ASCO 2025.
Elinzanetant reduces vasomotor symptoms from endocrine therapy in HR+ breast cancer, with rapid onset and good tolerability.
High CIG signature or high sTILs linked to better survival in stage I TNBC; findings support further prognostic evaluation.
About 1 in 10 patients with high RS early HR+/HER2- BC decline chemo, which is tied to worse overall survival, per ASCO data.
Oral paclitaxel (DHP107) shows non-inferior efficacy and manageable safety vs IV in HER2-negative metastatic breast cancer.
Trastuzumab rezetecan shows strong intracranial activity in HER2+ breast cancer with brain metastases in REIN trial.
Sacituzumab tirumotecan showed a 71% ORR and manageable safety in first-line advanced TNBC, regardless of PD-L1 status.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.